Lupin Partners with Exeltis to Market its Specialty Drug ‘Solosec’ in US
On Thursday, 27th January 2022, the pharmaceutical company ‘Lupin’ said that, it has now entered into an agreement with the company ‘Exeltis USA’ for the purpose of promoting the specialty antibacterial drug known as Solosec in the market of the United States. The company ‘Exeltis USA’ is going to be marketing the Solosec drug along […]
Continue Reading